Novel Applications of Thiosuccinyl-Crosslinked Hemoglobin Conjugates

Publication ID: 24-11857605_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Novel Applications of Thiosuccinyl-Crosslinked Hemoglobin Conjugates,” Published Technical Disclosure No. 24-11857605_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857605_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,605.

Summary of the Inventive Concept

This inventive concept leverages the core technology of thiosuccinyl-crosslinked hemoglobin conjugates to address various unmet needs in industries beyond pharmaceuticals, including agricultural pest control, bioremediation, cosmetics, environmental monitoring, and food processing.

Background and Problem Solved

The original patent disclosed thiosuccinyl-crosslinked hemoglobin conjugates for pharmaceutical applications, but their potential extends far beyond. This inventive concept addresses the limitations of existing solutions in other industries, where the conjugates' unique properties can provide significant benefits.

Detailed Description of the Inventive Concept

The new claims describe systems and methods that utilize thiosuccinyl-crosslinked hemoglobin conjugates in novel applications. For example, in agricultural pest control, the conjugate can deliver pesticides to targeted areas, reducing environmental impact. In bioremediation, the conjugate can bind to heavy metals, facilitating their removal from contaminated sites. Similarly, the conjugate can be used in cosmetics to deliver active ingredients to the skin, in environmental monitoring to detect pollutants, and in food processing to extend product shelf life.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the application of thiosuccinyl-crosslinked hemoglobin conjugates, moving beyond pharmaceuticals to address unmet needs in various industries. This inventive concept is non-obvious because it requires a deep understanding of the conjugates' properties and their potential to solve real-world problems in diverse fields.

Alternative Embodiments and Variations

Other embodiments of this inventive concept could include using different types of polymers or linkers, varying the molecular weight of the conjugate, or exploring alternative methods of administration or detection. These variations could further expand the conjugates' potential in various industries.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential, as it addresses pressing needs in multiple industries. The market for these applications is substantial, with potential customers including agricultural companies, bioremediation service providers, cosmetics manufacturers, environmental monitoring agencies, and food processing companies.

CPC Classifications

SectionClassGroup
A A61 A61K38/42
A A61 A61K47/542
A A61 A61K47/545
A A61 A61K47/60
A A61 A61P9/10

Field of Art

Biomedical engineering and polymer chemistry, specifically protein conjugation techniques involving hemoglobin modification, drug delivery systems, and biomolecular engineering with a focus on polyethylene glycol (PEG) conjugation strategies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in bioengineering or chemical engineering, possessing expertise in protein modification, polymer chemistry, and interdisciplinary applications of biomolecular conjugates, with knowledge of crosslinking techniques and polymer-protein interactions

Obviousness Rationale

A person having ordinary skill would recognize that the thiosuccinyl-crosslinked hemoglobin conjugates disclosed in the source patent inherently possess versatile properties that enable broad application across multiple technical domains. The fundamental molecular structure and crosslinking mechanism described in the source patent provide a predictable platform for extending the conjugate's utility beyond pharmaceutical applications. The PTD's proposed variations represent logical extensions of the core technological concept by leveraging the conjugate's inherent binding and delivery capabilities.

Obvious Combinations & Variations

Source Patent Element
Thiosuccinyl-crosslinked hemoglobin conjugate with polyethylene glycol attachment
PTD Variation
Agricultural pest control delivery system using the conjugate
Obviousness Reasoning
Known techniques for targeted molecular delivery make pesticide transport a predictable and straightforward application of the existing molecular platform
Source Patent Element
Covalent attachment of water-soluble polymers to tetrameric hemoglobin
PTD Variation
Bioremediation method for heavy metal binding
Obviousness Reasoning
The conjugate's inherent binding properties and polymer modification suggest a natural extension to environmental remediation applications
Source Patent Element
Polyethylene glycol conjugation with molecular weight between 1,000-50,000 Daltons
PTD Variation
Cosmetic delivery system for active ingredients
Obviousness Reasoning
The established molecular weight range and polymer attachment mechanism directly support transdermal and topical delivery strategies
Source Patent Element
Thiosuccinyl crosslinking moiety with flexible polymer attachment
PTD Variation
Environmental monitoring system for pollutant detection
Obviousness Reasoning
The conjugate's molecular structure inherently supports selective binding and detection mechanisms across different environmental contexts
35 U.S.C. § 103 Summary: Based on US Patent 11857605's disclosure of thiosuccinyl-crosslinked hemoglobin conjugates, the present publication demonstrates that the claimed variations represent obvious extensions of the prior art, employing known protein modification techniques to achieve predictable results in alternative technical domains. A person having ordinary skill in the art would readily recognize the inherent adaptability of the molecular platform disclosed in the source patent, rendering the proposed applications prima facie obvious under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,605
TitleThiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
Assignee(s)Billion King International Limited